ACELYRIN
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its expertise to rapidly advance these medicines to patients.
ACELYRIN
Industry:
Biopharma Biotechnology Health Care
Founded:
2020-01-01
Address:
Los Angeles, California, United States
Country:
United States
Website Url:
http://www.acelyrin.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
558 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro Google Tag Manager Google Analytics Content Delivery Network Amazon Global Site Tag HSTS IPv6
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Harmony Biosciences
Harmony Biosciences is a pharmaceutical company that develops and commercializes novel therapies for rare neurological disorders.
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Mirum Pharmaceuticals
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2023-01-05 | ValenzaBio | ValenzaBio acquired by ACELYRIN | N/A |
Investors List
Westlake Village BioPartners
Westlake Village BioPartners investment in Series C - ACELYRIN
Cowen Healthcare Investments
Cowen Healthcare Investments investment in Series C - ACELYRIN
OrbiMed
OrbiMed investment in Series C - ACELYRIN
Samsara BioCapital
Samsara BioCapital investment in Series C - ACELYRIN
Decheng Capital
Decheng Capital investment in Series C - ACELYRIN
Matrix Capital Management
Matrix Capital Management investment in Series C - ACELYRIN
venBio Partners
venBio Partners investment in Series C - ACELYRIN
Marshall Wace
Marshall Wace investment in Series C - ACELYRIN
Access Biotechnology
Access Biotechnology investment in Series C - ACELYRIN
Tybourne Capital Management
Tybourne Capital Management investment in Series C - ACELYRIN
Key Employee Changes
Official Site Inspections
http://www.acelyrin.com Semrush global rank: 5.78 M Semrush visits lastest month: 1.24 K
- Host name: 52.142.5.13
- IP address: 52.142.5.13
- Location: Washington United States
- Latitude: 38.7095
- Longitude: -78.1539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 22747
More informations about "ACELYRIN"
ACELYRIN - Crunchbase Company Profile & Funding
ACELYRIN is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of promising drug candidates and by leveraging its …See details»
ACELYRIN, INC. | SEC Filing
Organization and Business. ACELYRIN, INC. (the “Company”) is a late-stage clinical biopharma company focused on identifying, acquiring, and accelerating the development and …See details»
ACELYRIN | Our Story
ACELYRIN was co-founded in 2020 by Shao-Lee Lin and Bob Carey. About . Science . Community . Investors & Media Careers. Stories. Contact Us. Our Story. Our People Careers. …See details»
Acelyrin, Inc. - AnnualReports.com
ACELYRIN, INC. (Nasdaq: SLRN) is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of …See details»
ACELYRIN Company Profile | Management and Employees List
ACELYRIN Profile and History. ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating …See details»
ACELYRIN - Overview, News & Similar companies | ZoomInfo.com
Who is ACELYRIN. ACELYRIN, INC. is a biopharma company focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and …See details»
ACELYRIN, INC. - LinkedIn
ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing …See details»
Our People - ACELYRIN
The ACELYRIN Team. We are led by experienced biopharma executives with exceptional track records of building strong, innovative and diverse teams across the healthcare industry. Senior …See details»
Corporate Governance | ACELYRIN, INC.
The Board of Directors of ACELYRIN, INC. (the "Company") sets high standards for the Company's employees, officers and directors. Implicit in this philosophy is the importance of …See details»
Acelyrin, Inc. Company Profile | Agoura Hills, CA | Competitors ...
Find company research, competitor information, contact details & financial data for Acelyrin, Inc. of Agoura Hills, CA. Get the latest business insights from Dun & Bradstreet.See details»
ACELYRIN - Funding, Financials, Valuation & Investors - Crunchbase
ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies. ... How much funding has this organization …See details»
ACELYRIN - Contacts, Employees, Board Members, Advisors
Organization. ACELYRIN . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of Board …See details»
ACELYRIN, INC. - Company Profile & Staff Directory - ContactOut
ACELYRIN, INC. (Nasdaq: SLRN) is a Los Angeles area-based late-stage clinical biopharma company – with additional operations in the San Francisco Bay area – focused on providing …See details»
Accelerating Medicines to Transform Patients’ Lives - ACELYRIN, INC.
Foregoing that may impact ACELYRIN’s business; maintaining and defending IP protection; the ability to timely secure adequate supply of its product candidates; and legal proceedings, as …See details»
ACELYRIN | Our People
Executive Director and CEO of the TED Community Organization. Latest Press Releases. ... Press Release. ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of …See details»
ACELYRIN, INC. Announces Leadership Transition - Yahoo Finance
May 9, 2024 Mina Kim appointed Chief Executive Officer and to Board of Directors ACELYRIN Founder Shao-Lee Lin, M.D., Ph.D., steps down as Chief Executive Officer Shephard (Shep) …See details»
Acelyrin Terminates Izokibep After Failed Phase IIb/III Uveitis Data
6 days ago Acelyrin on Tuesday announced that it will discontinue the development of its investigational IL-17A blocker izokibep following a failed Phase IIb/III trial in uveitis.. The …See details»
Acelyrin says goodbye to the drug that got it a $540M IPO in 2023
6 days ago Acelyrin is officially ending development of an experimental medicine it referred to as a “diamond in the rough” and that served as ...See details»
Our Science - ACELYRIN
ACELYRIN can access promising therapeutic programs through our global network of relationships across pharma and biotech, finance and academia. Our Focus We conduct a …See details»
ACELYRIN | Careers And Job Opportunities
“I joined ACELYRIN because I wanted to be part of a small company where my contributions could positively impact the growth of the organization and drive its mission forward. I enjoy …See details»